The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
|Articles|May 18, 2012
Nippon Soda Co., Ltd.
Special low viscosity, super fine powder grade Nisso HPC-SSL-SFP is introduced as a new high performance dry binder for direct compression, ODT and extra-granule addition applications.
Advertisement
Special low viscosity, super fine powder grade Nisso HPC-SSL-SFP is introduced as a new high performance dry binder for direct compression, ODT and extra-granule addition applications. The excellent tablet properties that HPC is well known for as a wet binder can now be achieved in dry binding applications using very low levels of binder and with minimal-to-no impact on disintegration times and dissolution profiles.
When HPC-SSL-SFP is added to an Acetaminophen DC tablet (Acetaminophen 60%, Lactose/Corn Starch 24.5-36.5%, Binder 3-15%, Silica 0.5%) as a dry binder at 3% vs 15% for other typical dry binders, tablet hardness and friability are superior while disintegration time is fastest and dissolution time is not adversely impacted.
The highly compressible HPC-SSL-SFP is also effective in ODT formulations and in extra-granule dry binder addition applications.
Contact info:
Catherine Cote
Nisso America Inc.
88 Pine Street, 14th Fl
New York, NY 10005
+1-212-490-0350
Nisso Chemical Europe GmbH
Naoki Kuwada
+49-(0)-211-1306686-0
Advertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech Weekly Roundup—September 18, 2026
4
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
5